[{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.080000000000000002,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Catalent","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Catalent"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"D1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Esteve Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Esteve Pharmaceuticals"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Esteve Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Esteve Pharmaceuticals"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Biopas Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Etilevodopa","moa":"MAO","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Biopas Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Biopas Laboratories"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Etilevodopa","moa":"D1 receptor","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Catalent","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Catalent"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Esteve Huayi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Etilevodopa","moa":"Decarboxylase","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Esteve Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Esteve Pharmaceuticals"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Nepicastat","moa":"DBH","graph1":"Neurology","graph2":"Preclinical","graph3":"Acorda Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Acorda Therapeutics \/ Asieris Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Acorda Therapeutics \/ Asieris Pharmaceuticals"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Acorda Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Acorda Therapeutics"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Esteve Quimica","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Acorda Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Acorda Therapeutics"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Chance Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.14000000000000001,"dosageForm":"Powder for Inhalation","sponsorNew":"Acorda Therapeutics \/ Chance Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Chance Pharmaceuticals"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Termination","leadProduct":"Fampridine","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0.51000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.51000000000000001,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Acorda Therapeutics \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Merz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Etilevodopa","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Acorda Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.19,"dosageForm":"Inhalation Powder in Capsule","sponsorNew":"Acorda Therapeutics \/ Merz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Acorda Therapeutics \/ Merz Pharma"},{"orgOrder":0,"company":"Acorda Therapeutics","sponsor":"Merz Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Etilevodopa","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Acorda Therapeutics","amount2":0.19,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Acorda Therapeutics \/ Merz Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"Acorda Therapeutics \/ Merz Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Acorda Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Merz purchases substantially all of the assets of Acorda, including the rights to Inbrija (levodopa inhalation powder), which is used when needed for OFF episodes in adults with Parkinson's disease.

                          Brand Name : Inbrija

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 10, 2024

                          Lead Product(s) : Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Merz Therapeutics

                          Deal Size : $185.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Merz Therapeutics will acquire Acorda's assets, including Inbrija (levodopa inhalation) for OFF episodes in Parkinson’s and Ampyra (dalfampridine).

                          Brand Name : Inbrija

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 02, 2024

                          Lead Product(s) : Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Merz Pharma

                          Deal Size : $185.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Following termination, Acorda regains global commercialization rights to Fampyra, a prolonged-release formulation of fampridine (4-aminopyridine) for adults with multiple sclerosis.

                          Brand Name : Fampyra

                          Molecule Type : Small molecule

                          Upfront Cash : $110.0 million

                          January 11, 2024

                          Lead Product(s) : Fampridine

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Biogen

                          Deal Size : $510.0 million

                          Deal Type : Termination

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : INBRIJA® (levodopa) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa. INBRIJA utilizes ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inha...

                          Brand Name : Inbrija

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 06, 2023

                          Lead Product(s) : Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The collaboration aims to provide INBRIJA® in China. Inbrija (levodopa) is indicated in the United States for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase...

                          Brand Name : Inbrija

                          Molecule Type : Small molecule

                          Upfront Cash : $2.5 million

                          May 08, 2023

                          Lead Product(s) : Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Chance Pharmaceuticals

                          Deal Size : $144.0 million

                          Deal Type : Agreement

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Inbrija (levodopa) is levodopa/dopa-decarboxylase inhibitor, it is converted to dopamine replacement agent for the intermittent treatment of episodic motor fluctuations of Parkinson disease.

                          Brand Name : Inbrija

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 07, 2023

                          Lead Product(s) : Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Recipient : Esteve Quimica

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : INBRIJA® (levodopa) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa. INBRIJA utilizes ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inha...

                          Brand Name : Inbrija

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 05, 2023

                          Lead Product(s) : Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Recipient : Catalent Pharma Solutions

                          Deal Size : $10.0 million

                          Deal Type : Agreement

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : SYN117 (nepicastat), is a small molecule drug and the license agreement provides for its development for all non-psychiatric indications and therapeutic uses. The asset has been held by Acorda’s U.S. subsidiary, Biotie Therapies, Inc.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : $0.5 million

                          August 29, 2022

                          Lead Product(s) : Nepicastat

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Asieris Pharmaceuticals

                          Deal Size : $7.5 million

                          Deal Type : Licensing Agreement

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) is indicated in the EU for the intermittent treatment of episodic motor uctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibito...

                          Brand Name : Inbrija

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 16, 2022

                          Lead Product(s) : Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Esteve Huayi Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the terms of the agreements, Acorda will receive a significant percentage of the selling price of INBRIJA in Latin America in exchange for supply of the product. Biopas plans on seeking marketing authorization in all countries to make Inbrija avail...

                          Brand Name : Inbrija

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          May 11, 2022

                          Lead Product(s) : Etilevodopa

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Biopas Laboratories

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank